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Background: Gemcitabine plus carboplatin (GCa) chemotherapy has 
shown to have activity against non-small cell lung cancer (NSCLC) and 
to be a well-tolerated treatment. Our aim was to evaluate the feasibility 
and clinical efﬁcacy of adjuvant bi-weekly GCa in completely resected 
stage IA (>2cm) to IIIA NSCLC.
Methods: Eligibility required completely resected stage IA (>2cm) to 
IIIA NSCLC, no prior chemotherapy or radiotherapy, ECOG PS 0-1, 
age under 76 years. Patients were to receive four cycles, each at 4-week 
intervals, of G (1000mg/m2, d 1, 15) and Ca (AUC 2.5, d 1, 15).Cycles 
were repeated until 4 treatments.
Results: Between 03/2005 and 10/2006, 56 pts were enrolled and 54 
pts were eligible, data on 45 pts (30 male and 15 female, median age 64 
years) were currently evaluated. ECOG PS 0:1 =42:3, Stage I:II:IIIA 
=31: 9: 5, Histology adeno:squamous:others =37: 7: 3. Median number 
of GCa treatments was 4(1-4) and median dose intensity was 94% 
for both G and Ca. Grade 3/4 hematological events included leukope-
nia(7%), neutoropenia (7%), and anemia (4%). Grade 3/4 non-hemato-
logical events included nausea (2%), infection (4%). Preliminary 1 year 
disease-free survival was 83%.
Conclusions: Adjuvant bi-weekly schedule of gemcitabine plus 
carboplatin was feasible with acceptable level of toxicity in completely 
resected stage IA (>2cm) to IIIA non-small cell lung cancer. Disease-
free and overall survival are still under evaluation.
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Limited surgery for elderly patients with non-small cell lung cancer 
who have high risk for lobectomy: Comparison of the short- and 
the long-term outcomes with standard surgery
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Background: The incidence of lung cancer in the elderly is increas-
ing in many countries. Although lobectomy is the standard of care for 
early-stage lung cancer even in the elderly, segmentectomy and wedge 
resection are commonly provided in the elderly to reduce operative 
risk. However, the short- and the long-term effects of such procedures 
remain unclear. The aim of this study was to determine the signiﬁcance 
of compromised limited surgery in the elderly.
Methods: The medical records of 116 patients (75 or older) who under-
went pulmonary resection for clinical stage I from 1991 to 2003 were 
analyzed retrospectively. The patients were divided into two groups; 
the compromised limited surgery group (CLS) (the patients who 
underwent sublobar resection due to their impaired physical condition) 
and the standard surgery group (SS). The clinical variables, operative 
complications, and survival were compared between two groups. 
Results: CLS was performed for 43 patients and SS for 73. Median 
age was 77 years old (range 75-87) consisting of 76 males. There were 
80 adenocarcinomas, 25 squamous carcinomas, and 11 others. Median 
follow-up period was 1136 days. The reasons for CLS were poor pul-
monary function for 17, cerebro- or cardio-vascular diseases for 17, and 
others for 9 patients. Pathological stage was I in 93 patients. There was 
no signiﬁcant association between surgical procedures and these clini-
cal variables. Operative mortality was 0% after CLS and 0.9% (n=1) 
after SS. Operative complications and cause of death was summarized 
in table. There was no signiﬁcant difference of operative complications 
(mild or severe) between the two groups. Overall survival at 1, 3, and 5 
years after CLS (SS) was 98% (90), 70% (80), and 66% (68) (Figure). 
Conclusion: In the elderly patients, limited resections can be an equiv-
alent alternative for patients who are estimated to have high operative 
risk for lobectomy.
